Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer
- 30 June 2011
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 80 (4), 598-609
- https://doi.org/10.1124/mol.111.073627
Abstract
Pancreatic cancer is an aggressive neoplasm, with a mortality rate close to 100%. The most successful agent for pancreatic cancer treatment is gemcitabine, although the overall effect in terms of patient survival remains very poor. This study was initiated to evaluate a novel class of anticancer agents against pancreatic cancer. This group of compounds belongs to the dipyridyl thiosemicarbazone class that have been shown to have potent and selective activity against a range of different neoplasms in vitro and in vivo. We demonstrate for the first time in pancreatic cancer that these agents increase the expression of the growth and metastasis suppressor N-myc downstream-regulated gene 1 and its phosphorylation at Ser330 and Thr346 that is important for its activity against this tumor. In addition, these agents increased expression of the cyclin-dependent kinase inhibitor p21CIP1/WAF1, whereas decreasing cyclin D1 in pancreatic cancer cells. Together, these molecular alterations account, in part, for the pronounced antitumor activity observed. Indeed, these agents had significantly higher antiproliferative activity in vitro than the established treatments for pancreatic cancer, namely gemcitabine and 5-fluorouracil. Studies in vivo demonstrated that a novel thiosemicarbazone, namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochloride, completely inhibited the growth of pancreatic cancer xenografts with no evidence of marked alterations in normal tissue histology. Together, our studies have identified molecular effectors of a novel and potent antitumor agent that could be useful for pancreatic cancer treatment.This publication has 42 references indexed in Scilit:
- Second-line therapy for advanced pancreatic cancer: A review of the literature and future directionsCancer Treatment Reviews, 2009
- A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreasInvestigational New Drugs, 2008
- NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease statesCarcinogenesis: Integrative Cancer Research, 2007
- Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletionBlood, 2007
- Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabineBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancerBritish Journal of Cancer, 2006
- The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesisCarcinogenesis: Integrative Cancer Research, 2006
- Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenograftsEuropean Journal Of Cancer, 2004
- Evaluation of new iron chelators and their therapeutic potentialInorganica Chimica Acta, 2002
- The p21Cip1 and p27Kip1 CDK `inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblastsThe EMBO Journal, 1999